ADA 2010: Blood-pressure target for high-risk type 2 diabetics still an open question
July 1st 2010At 5 years? follow-up, intensive blood-pressure reduction to a target systolic blood pressure (SBP) less than 120 mm Hg did not reduce the risk of a composite cardiovascular outcome, compared with a target SBP of less than 140 mm Hg in patients with type 2 diabetes at high risk of cardiovascular events, although it did reduce the incidence of stroke, said William Cushman, MD, who presented the results from the blood pressure portion of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study to a gathering at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Fla.
ADA 2010: Diabetic retinopathy reduced by intensive glucose control, but risk of death increases
July 1st 2010Five-year data from a seminal study in patients with type 2 diabetes who are at especially high risk of heart disease show that intensive glucose control does slow the progression of microvascular disease, but mortality is increased and there is no benefit on macrovascular complications.
ADA 2010: Findings add fuel to the rosiglitazone controversy
July 1st 2010A new post-hoc study of rosiglitazone and cardiac events in patients with type 2 diabetes is adding to the controversy surrounding the thiazolidinedione (TZD) agent. Lead author Richard Bach, MD, associate professor of medicine, Washington University, St. Louis, Mo., presented the new data during a late-breaking clinical study symposium Tuesday morning at the 70th Scientific Sessions of the American Diabetes Association, taking place in Orlando, Fla.
ADA 2010: Community-based lifestyle program helps overweight/obese shed pounds, lower blood glucose
July 1st 2010A community-based behavioral lifestyle intervention results in significant reductions in glycated hemoglobin, fasting blood glucose, and body weight in overweight/obese individuals with prediabetes, said David Goff Jr, MD, PHD.
ADA 2010: Gut bacteria can affect obesity
June 30th 2010Obesity and leanness are more than calories in and energy out. The amount of adipose tissue an individual carries is also a function of his or her intestinal microbiota. Research in mice and humans suggests that individuals with more Firmicutes and fewer Bacteroidetes tend to be more obese.
ADA 2010: Will DPP-4 inhibitors replace sulfonylureas? Debaters make their case
June 30th 2010Although their ability to control glycemia is essentially the same, do other merits of dipeptidyl peptidase 4 (DPP-4) inhibitors favor their replacing sulfonylureas in the treatment armamentarium for type 2 diabetes? Michael Nauck, MD, and David Matthews, FRCP, were on opposing sides of this issue.
ADA 2010: Glycated hemoglobin levels correlate strongly to future diabetes, cardiovascular risk
June 29th 2010An ancillary study to the ARIC (Atherosclerosis Risk in Communities) study supports the most recent (2010) ADA risk categories of glycated hemoglobin in identifying future risk of developing diabetes and macrovascular and microvascular disease.
ADA 2010: Liraglutide more successful than sitagliptin in achieving glycemic target
June 28th 2010Liraglutide is more successful in reducing glycated hemoglobin levels to 7% or less regardless of baseline glycated hemoglobin level compared with sitagliptin in adults with type 2 diabetes, said Melanie Davies, MD, MB ChB, professor of diabetes medicine, University of Leicester, United Kingdom.